Thymosin Alpha-1 (TA1)

Thymosin Alpha-1 (TA1) (Inj)

Thymosin alpha‑1 (TA1; thymalfasin) is a 28‑amino‑acid peptide derived from thymosin fraction 5, studied for immune modulation. It is used in some countries for chronic viral infections and as an immune adjuvant in oncology and sepsis research.

Dosing Protocols

— 5 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 300–500 mcg once daily (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C or freeze at −20 °C; reconstituted: refrigerate and use within 7 days.

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support immune modulation and enhance host defense mechanisms.

Frequency: Inject once daily subcutaneously. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges.

Phase	Dose	Syringe (U-100)
Week 1	300 mcg (0.3 mg)	18 units (0.18 mL)
Weeks 2–8	500 mcg (0.5 mg)	30 units (0.30 mL)

— 10 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 300–500 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C or freeze at −20 °C; reconstituted: refrigerate and use within 7 days.

Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Support immune modulation and enhance host defense mechanisms.

Frequency: Inject once daily subcutaneously. The 500 mcg daily dose yields ~3.5 mg/week, consistent with clinical dosing ranges.

Phase	Dose	Syringe (U-100)
Week 1	300 mcg (0.3 mg)	9 units (0.09 mL)
Weeks 2–8	500 mcg (0.5 mg)	15 units (0.15 mL)

Benefits

• Immune system modulation (enhanced T-cell function)
• Studied in chronic viral infections (e.g., hepatitis B/C) as adjunct therapy
• May improve vaccine response as an adjuvant (research)
• Investigated in oncology for immune support alongside standard care
• Potential reduction of infection risk in immunocompromised settings (research)
• Studied in sepsis/COVID-19 immune dysregulation contexts (mixed evidence)

Mechanism of Action

Binds to immune cell receptors and modulates innate/adaptive immunity. Reported to promote T-cell differentiation and function, increase Th1 cytokines (e.g., IL‑2, IFN‑γ), enhance dendritic cell activity, and modulate toll-like receptor signaling. Acts as an immunorestorative rather than a broad stimulant.

Side Effects

• Injection site redness/pain
• Fatigue
• Headache
• Nausea
• Flu-like symptoms (rare)
• Rash

Side Effect Management

• Rotate injection sites
• Dose in evening if fatigue occurs
• Hydration/rest for flu-like symptoms
• Discontinue and evaluate if significant rash or hypersensitivity

Contraindications

• Known hypersensitivity to TA1
• Pregnancy/breastfeeding (insufficient data)
• Organ transplant recipients on immunosuppression (may interfere)
• Autoimmune disease flare risk—use caution and medical supervision

Research Citations

PubMed/DOI-linked citations for verification. Many studies are preclinical (animal/in-vitro) or early clinical.

1. Garaci E et al. Thymosin alpha1: from bench to bedside. (review) DOI Link
2. Romani L et al. Thymosin alpha1: an endogenous regulator of immune responses (review). DOI Link
3. Sherman KE et al. Thymosin alpha1 and interferon in chronic hepatitis C (trial). DOI Link
4. Wang C et al. Thymosin alpha1 in sepsis: randomized trial/meta-analysis context. DOI Link

---